Collaborative Study: The Protective Value of Medical Data
The purpose of this study was to evaluate the protective value offered by IntelliScript’s Medical Data product and the types of risks/impairments that it helps identify.
The purpose of this study was to evaluate the protective value offered by IntelliScript’s Medical Data product and the types of risks/impairments that it helps identify.
Munich Re Life US assessed Milliman Irix® – Risk Score with Medical Data, a predictive modeling tool developed and owned by Milliman that assesses mortality risk through the combination of an individual’s prescription drug history and medical claims records.
A recent article published by Clinical Reference Lab and ExamOne showed the protective value for tobacco testing exceeded $4 billion. Using the same time frame (2015-2022) and 18 million record dataset, we now describe the additional value associated with testing for undiagnosed diabetes and hypertension worth $2.6 billion.
The number of people living after a cancer diagnosis (i. e. prevalent cases) has been increasing for the past 30 years, reaching around 5 % of the total population in several countries.
The industry is still wrestling with mortality assumptions related to Covid-19, and how shifts may affect the life insurance underwriting process.
RGA's Melissa Gallegos provides an overview of current foreign travel risk and urges insurers to remain vigilant and view every country as a world of its own.
As younger, tech-savvy consumers have increasingly completed their purchasing online, many life insurers have seized this opportunity to update and redesign their application and underwriting processes.
In just a few months’ time, the COVID-19 crisis brought about years of change in the way companies in all sectors and regions do business. According to a new McKinsey Global Survey of executives, their companies have accelerated the digitization of their customer and supply-chain interactions and of their internal operations by 3 to 4 years. And the share of digital or digitally enabled products in their portfolios has accelerated by a shocking 7 years. The insurance industry is no exception.
Part 1 in a series of 2 articles: Principles to consider
When asked to write on advances in impaired risk underwriting, I began to question the term “advances.”